title: Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?
abstract: Prior studies have suggested that loss of plasma cell CD56 expression in multiple myeloma defines a unique patient subset and that CD56 expression reliably discriminates between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). We conducted a study of 68 untreated patients with MM from a single institution to define the clinicopathological correlates of CD56 expression. We find CD56 expression in 55% of MM. Lack of CD56 expression does not define a unique clinicopathological or prognostic entity in MM. Strong CD56 expression can also be found in MGUS and does not help to distinguish from MM.
authors.affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
authors.forename: P
authors.initials: P
authors.lastname: Mathew
authors.forename: G J
authors.initials: GJ
authors.lastname: Ahmann
authors.forename: T E
authors.initials: TE
authors.lastname: Witzig
authors.forename: P C
authors.initials: PC
authors.lastname: Roche
authors.forename: R A
authors.initials: RA
authors.lastname: Kyle
authors.forename: P R
authors.initials: PR
authors.lastname: Greipp
mesh_terms: D015703:Antigens, CD / Q000378:metabolism*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism*; D019002:CD56 Antigen; D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis / Q000276:immunology*; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D019002:CD56 Antigen